Pharmacotherapy

Switching to dual GIP/GLP-1 receptor agonist lowers insulin needs in T2DM

April 2, 2025

Study details: This retrospective cohort study included 66 patients with T2DM who transitioned from a GLP-1 RA to tirzepatide (a dual GIP/GLP-1 RA) while concurrently using insulin therapy. Participants had been on a GLP-1 RA for at least six months before transitioning to the dual agonist therapy.

Results: The findings revealed a significant reduction in insulin requirements post-transition. Median insulin dose was lowered from 101 units at baseline to 71 units after 6 months, with a median decrease of 9.5 units. The median percent change in insulin dose was -9.2%. Patients with a baseline A1c of ≤8.0% required a larger decrease in insulin relative to those with a higher baseline A1c. Tirzepatide was well-tolerated, with fewer reported adverse effects compared with the previous GLP-1 receptor agonist regimen.

Clinical impact: Dual GIP/GLP-1 receptor agonist therapy could be a more effective and tolerable option for managing T2DM, potentially reducing the need for exogenous insulin and enhancing overall glycemic control. This transition may offer a promising alternative for patients struggling with insulin management and side effects from GLP-1 RAs.

Source:

Lahey AM, et al. (2025, March 19). Pharmacotherapy. Insulin requirements after switching from GLP-1 receptor agonist to dual GIP/GLP-1 receptor agonist in patients with type 2 diabetes mellitus. https://pubmed.ncbi.nlm.nih.gov/40108854/